Recent Updates
Recently added Catalysts

RT-111

Phase 1

Healthy Volunteers | Small molecule | Other |Rani Therapeutics Holdings, Inc.|Last Updated: Jan 10, 2024

Target and mechanism

ModalitySmall molecule

Also known as RT-111 (0.5mg)

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment55

FDA Designations

No designations recorded

Clinical trial landscape

RT-111 · 1 trial · 1 indication

Phase 1 1
NCT05890118Study Evaluating PK of Ustekinumab Administered Orally Via RaniPill™ CapsuleHealthy Volunteers
COMPLETED55 Analytics
PHASE1COMPLETED
Study Evaluating PK of Ustekinumab Administered Orally Via RaniPill™ Capsule
Healthy Volunteers
NCT0589011855
Unlock trial analytics

Study Design & Arms

Interventions

NameTypeDescription
StelaraDRUGA commercial formulation of ustekinumab for SC control (0.5mg)
RT-111 (0.5mg)COMBINATION_PRODUCTRaniPill capsule containing ustekinumab with a dose of 0.5mg
RT-111 (0.75mg)COMBINATION_PRODUCTRaniPill capsule containing ustekinumab with a dose of 0.75mg
Unlock Study Design Details